LU92098I2 - Adalimumab et ses dérivés pharmaceutiquement acceptables (HUMIRA®) - Google Patents

Adalimumab et ses dérivés pharmaceutiquement acceptables (HUMIRA®)

Info

Publication number
LU92098I2
LU92098I2 LU92098C LU92098C LU92098I2 LU 92098 I2 LU92098 I2 LU 92098I2 LU 92098 C LU92098 C LU 92098C LU 92098 C LU92098 C LU 92098C LU 92098 I2 LU92098 I2 LU 92098I2
Authority
LU
Luxembourg
Prior art keywords
humira
adalimumab
pharmaceutically acceptable
acceptable derivatives
tnf
Prior art date
Application number
LU92098C
Other languages
English (en)
Original Assignee
Kennedy Trust For Rheumatology Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24773909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92098(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kennedy Trust For Rheumatology Res filed Critical Kennedy Trust For Rheumatology Res
Publication of LU92098I2 publication Critical patent/LU92098I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
LU92098C 1996-08-01 2012-11-16 Adalimumab et ses dérivés pharmaceutiquement acceptables (HUMIRA®) LU92098I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/690,775 US6270766B1 (en) 1992-10-08 1996-08-01 Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease

Publications (1)

Publication Number Publication Date
LU92098I2 true LU92098I2 (fr) 2013-01-16

Family

ID=24773909

Family Applications (4)

Application Number Title Priority Date Filing Date
LU92004C LU92004I2 (fr) 1996-08-01 2012-05-23 adalimumab et ses dérivés pharmaceutiquement acceptables (HUMIRA®)
LU92005C LU92005I2 (fr) 1996-08-01 2012-05-23 golimumab et ses dérivés pharmaceutiquement acceptables (SIMPONI®)
LU92099C LU92099I2 (fr) 1996-08-01 2012-11-16 Golimumab et ses dérivés pharmaceutiquement acceptables (SIMPONI®)
LU92098C LU92098I2 (fr) 1996-08-01 2012-11-16 Adalimumab et ses dérivés pharmaceutiquement acceptables (HUMIRA®)

Family Applications Before (3)

Application Number Title Priority Date Filing Date
LU92004C LU92004I2 (fr) 1996-08-01 2012-05-23 adalimumab et ses dérivés pharmaceutiquement acceptables (HUMIRA®)
LU92005C LU92005I2 (fr) 1996-08-01 2012-05-23 golimumab et ses dérivés pharmaceutiquement acceptables (SIMPONI®)
LU92099C LU92099I2 (fr) 1996-08-01 2012-11-16 Golimumab et ses dérivés pharmaceutiquement acceptables (SIMPONI®)

Country Status (12)

Country Link
US (10) US6270766B1 (fr)
EP (3) EP1941904B1 (fr)
AT (2) ATE535255T1 (fr)
AU (1) AU719015B2 (fr)
CA (2) CA2261630C (fr)
DE (1) DE69734317T2 (fr)
DK (3) DK0914157T3 (fr)
ES (3) ES2247635T3 (fr)
HK (1) HK1020011A1 (fr)
LU (4) LU92004I2 (fr)
PT (2) PT1941904E (fr)
WO (1) WO1998005357A1 (fr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002078A1 (fr) 1989-08-07 1991-02-21 Peptide Technology Ltd Ligands de liaison du facteur de necrose de tumeurs
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) * 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US7070783B1 (en) 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU228630B1 (en) * 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
PT942740E (pt) 1996-12-06 2004-01-30 Amgen Inc Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
EP1352656A3 (fr) * 1996-12-06 2004-02-04 Amgen Inc. Thérapie combinatoire utilisant une protèine de liaison du facteur de nécrose tumorale (TNF) dans le traitement de maladies induites par le TNF
AU7345798A (en) * 1997-05-12 1998-12-08 Kennedy Institute Of Rheumatology, The Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
HUP0103563A3 (en) * 1998-08-31 2004-04-28 Biogen Idec Ma Inc Cambridge Method of modulating memory effector t-cells and compositions
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
DK1176981T3 (da) 1999-05-07 2006-04-10 Genentech Inc Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer
US6544504B1 (en) 1999-07-28 2003-04-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
AU6376700A (en) * 1999-07-28 2001-02-19 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
CA2876779A1 (fr) 2000-05-12 2001-11-22 Genzyme Corporation Modulateurs de marquage du tnf-.alpha.
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
MXPA03007878A (es) * 2001-03-02 2004-07-08 Medimmune Inc Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina.
EP1379275A4 (fr) * 2001-03-14 2005-12-21 Centocor Inc Proteines provenant de l'immunoglobuline associees a la bronchopneumopathie chronique obstructive, compositions, procedes et utilisations
EP1390077B1 (fr) 2001-05-02 2014-07-16 Purdue Research Foundation Traitement et diagnostic de maladies associees aux macrophages
CA2868614A1 (fr) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
AU2002320352A1 (en) * 2001-07-24 2003-02-17 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
US8043603B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
MXPA05000815A (es) * 2002-07-19 2005-04-28 Abbott Biotech Ltd Tratamiento de trastornos relacionados con tnfa.
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US7217718B2 (en) * 2002-11-21 2007-05-15 Genzyme Corporation Induction of immune tolerance
ES2363914T3 (es) * 2002-11-21 2011-08-19 Genzyme Corporation Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
WO2004050683A2 (fr) 2002-12-02 2004-06-17 Abgenix, Inc. Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
WO2004053064A2 (fr) * 2002-12-05 2004-06-24 Pharmacia Corporation Fragment fab' génétiquement modifié anti-facteur de nécrose tumorale alpha combiné à des médicaments antirhumatismaux modifiant l'évolution de la maladie
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP1460088A1 (fr) * 2003-03-21 2004-09-22 Biotest AG Anticorps humanisé contre CD4 avec des caractéristiques immunosuppressives
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2004110250A2 (fr) 2003-05-30 2004-12-23 Purdue Research Foundation Procede de diagnostic de l'atherosclerose
NZ544367A (en) * 2003-06-25 2009-12-24 Elan Pharm Inc Combination therapy involving methotrexate for treating rheumatoid arthritis
DE60331598D1 (de) * 2003-07-25 2010-04-15 Silanes Sa De Cv Lab Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
BRPI0507404A (pt) * 2004-02-06 2007-06-26 Astellas Us Llc método de tratamento de um indivìduo que tem psorìase e kit
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CA2565804A1 (fr) * 2004-05-04 2005-12-01 Genaissance Pharmaceuticals, Inc. Marqueurs haplotypes et procedes d'utilisation de ceux-ci pour determiner la reponse a un traitement
CA2565259A1 (fr) * 2004-05-07 2005-12-08 Astellas Us Llc Polypeptide lfa-3 soluble destine a traiter de troubles viraux
WO2006041970A2 (fr) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Infection a virus respiratoire syncytial (rsv)
EP1827469A2 (fr) * 2004-11-22 2007-09-05 Henry J. Smith Recepteurs cellulaires utilises comme excipients pour composes pharmaceutiques servant dans le traitement de l'arthrite, et des troubles inflammatoires et immunitaires
CN101128152A (zh) * 2004-12-23 2008-02-20 普渡研究基金会 发射正电子段层成像方法
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
EP1885388B1 (fr) * 2005-05-10 2013-09-11 Biogen Idec MA Inc. Traitement et evaluation des troubles inflammatoires
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2007038346A2 (fr) 2005-09-23 2007-04-05 Purdue Research Foundation Procede et dispositif de cytometrie en flux in vivo multiphoton
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
AU2016203976B2 (en) * 2005-11-09 2018-02-01 Abt Holding Company Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
NZ570616A (en) 2006-01-23 2012-07-27 Athersys Inc Multipotent adult progenitor cell therapeutics without adjunctive immunosuppressive treatment
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2666472A3 (fr) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de l'arthrite psoriasique
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
EP2010214A4 (fr) 2006-04-10 2010-06-16 Abbott Biotech Ltd Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP5535623B2 (ja) 2006-06-30 2014-07-02 アッヴィ バイオテクノロジー リミテッド 自動注射装置
US20080064626A1 (en) * 2006-09-08 2008-03-13 Zanella John M Methods of treating tendonitis in a subject by using an anti-cytokine agent
TWI414531B (zh) 2006-10-12 2013-11-11 Genentech Inc 淋巴毒素α之抗體
CA2668197A1 (fr) 2006-11-03 2008-05-15 Philip S. Low Procede de cytometrie en flux ex vivo et dispositif
WO2008098112A2 (fr) 2007-02-07 2008-08-14 Purdue Research Foundation Procédé d'imagerie de tomographie par émission de positrons
AR066016A1 (es) * 2007-04-11 2009-07-15 Alcon Res Ltd Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
EP2164525A2 (fr) * 2007-05-25 2010-03-24 Purdue Research Foundation Methode d'imagerie d'infections localisees
NZ581742A (en) 2007-06-08 2012-09-28 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
WO2008154543A2 (fr) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Procédés de traitement de l'arthrite idiopathique juvénile
KR20100120289A (ko) 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 분말상 단백질 조성물 및 이의 제조 방법
CA2718191C (fr) * 2008-03-13 2018-05-15 Biotest Ag Agent pour traiter une maladie
AU2009224690B2 (en) * 2008-03-13 2014-10-09 Biotest Ag Agent for treating disease
KR20100135257A (ko) * 2008-03-13 2010-12-24 바이오테스트 아게 질병 치료제
PT2341937E (pt) * 2008-09-29 2015-02-18 Biotest Ag Composição para tratamento de doença
US20100203146A1 (en) * 2009-02-09 2010-08-12 Callisto Pharmaceuticals, Inc. Intermittent dosing strategy for treating rheumatoid arthritis
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
CN102770458A (zh) * 2009-12-02 2012-11-07 阿塞勒隆制药公司 用于增加Fc融合蛋白的血清半寿期的组合物和方法
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
CN104105691A (zh) 2011-11-08 2014-10-15 艾尼纳制药公司 G蛋白偶联mas受体调节剂及对与其相关的病症的治疗
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
NZ703532A (en) * 2012-07-05 2018-02-23 Taiwan Liposome Co Ltd Methods of treating arthritis
US8958362B2 (en) * 2012-08-24 2015-02-17 William Marsh Rice University Method and system for wirelessly transmitting data
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
CN104955480A (zh) 2013-01-25 2015-09-30 西蒙有限公司 用于选择性减少循环的生物活性可溶性tnf的组合物以及用于治疗tnf介导的疾病的方法
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014182673A1 (fr) 2013-05-07 2014-11-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur mas couplé à la protéine g et traitement de troubles apparentés
TWI516272B (zh) 2013-06-05 2016-01-11 財團法人工業技術研究院 應用於生髮之方法及醫藥組成物
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10298750B2 (en) * 2013-11-21 2019-05-21 Vodafone Ip Licensing Limited Telecommunication networks for content delivery and lawful interception, content filtering and further content services using a SAVI platform
US9402876B2 (en) 2013-11-27 2016-08-02 Industrial Technology Research Institute Method and pharmaceutical composition for hair growth
KR102372512B1 (ko) * 2017-11-20 2022-03-10 가톨릭대학교 산학협력단 폴리감마글루탐산 및 메토트렉세이트를 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물
CN116688094A (zh) * 2021-12-15 2023-09-05 苏州澳宗生物科技有限公司 p75细胞外结构域在类风湿性关节炎治疗和/或预防中的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4695459A (en) 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0247091B1 (fr) 1985-11-01 1993-09-29 Xoma Corporation Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8608068D0 (en) 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
US5096906A (en) 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
EP0288088B1 (fr) 1987-04-24 1994-03-09 Teijin Limited Détection du facteur nécrosant de tumeur; anticorps monoclonal et composition
GB8805792D0 (en) 1988-03-11 1988-04-13 Celltech Ltd Medicaments
US5260422A (en) 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
GB8912497D0 (en) 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
JPH05503919A (ja) * 1989-06-13 1993-06-24 スミスクライン・ビーチャム・コーポレイション 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
WO1991002078A1 (fr) 1989-08-07 1991-02-21 Peptide Technology Ltd Ligands de liaison du facteur de necrose de tumeurs
US5298396A (en) 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
ATE143377T1 (de) 1989-12-27 1996-10-15 Centocor Inc Schimäre immunoglobuline für cd4-rezeptoren
DE4006269A1 (de) 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5958413A (en) 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
GB9023783D0 (en) 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
AU8910891A (en) 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
DE4108204A1 (de) 1991-03-14 1992-09-17 Schering Ag Verfahren zur herstellung von alkoxymagnesiumhalogeniden
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DK0610201T4 (da) 1991-03-18 2008-02-04 Centocor Inc Monoklonale og kimære antistoffer, der er specifikke for human tumornekrosefaktor
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5770401A (en) 1991-10-15 1998-06-23 Mullarkey; Michael F. Methods and compositions for treating allergic reactions
US5201329A (en) * 1992-01-21 1993-04-13 Claire Quackenbush Permanent wave rod having hinged end-cap
US5580874A (en) 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2123593C (fr) 1992-09-15 2000-03-14 Craig A. Smith Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale
WO1995009652A1 (fr) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Traitement des troubles auto-immuns et inflammatoires
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5741488A (en) * 1992-10-08 1998-04-21 The Kennedy Institute For Rheumatology Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
DE4320157A1 (de) 1993-06-18 1994-12-22 Bayer Ag Verwendung von 1,2,4-Dithiazolium-Salzen als Chemotherapeutica
EP0710121B1 (fr) 1993-07-30 2000-10-11 Kennedy Institute Of Rheumatology Procede de traitement de la sclerose en plaques
WO1995010538A1 (fr) 1993-10-15 1995-04-20 The University Of North Carolina At Chapel Hill Adn codant le recepteur humain p2u et cellules nulles exprimant les recepteurs p¿2u?
US20020068057A1 (en) 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US6190691B1 (en) * 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
GB2289218A (en) 1994-05-06 1995-11-15 Merck & Co Inc Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor
US5525613A (en) * 1994-06-16 1996-06-11 Entropin, Inc. Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5530157A (en) * 1995-02-16 1996-06-25 Scios Nova Inc. Anti-inflammatory benzoic acid derivatives
CA2218522A1 (fr) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU228630B1 (en) 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
AU2012202134B2 (en) 1996-08-01 2013-02-14 The Kennedy Trust For Rheumatology Research Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
DE19650115C1 (de) 1996-12-03 1998-07-02 Fraunhofer Ges Forschung Medikamenten-Dosiervorrichtung
PT942740E (pt) 1996-12-06 2004-01-30 Amgen Inc Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
EP4006269B1 (fr) 2021-11-15 2023-12-27 E-Parktower GmbH Dispositif de stockage / stationnement pour véhicules

Also Published As

Publication number Publication date
DE69734317T2 (de) 2006-07-20
EP0914157B1 (fr) 2005-10-05
ES2378446T3 (es) 2012-04-12
AU719015B2 (en) 2000-05-04
CA2261630A1 (fr) 1998-02-12
DK0914157T3 (da) 2006-01-30
ES2388244T3 (es) 2012-10-11
US8298537B2 (en) 2012-10-30
US20120141475A1 (en) 2012-06-07
CA2261630C (fr) 2012-12-04
US20110123543A1 (en) 2011-05-26
US20120141474A1 (en) 2012-06-07
LU92099I2 (fr) 2013-01-16
ES2247635T3 (es) 2006-03-01
EP1593393A2 (fr) 2005-11-09
US20020010180A1 (en) 2002-01-24
PT1941904E (pt) 2012-08-03
LU92005I2 (fr) 2012-07-23
EP1941904A3 (fr) 2009-09-09
EP0914157A1 (fr) 1999-05-12
US7838489B2 (en) 2010-11-23
US20020136723A1 (en) 2002-09-26
ATE305798T1 (de) 2005-10-15
EP1941904A2 (fr) 2008-07-09
US8383120B2 (en) 2013-02-26
US20090175859A1 (en) 2009-07-09
US6270766B1 (en) 2001-08-07
EP1593393A3 (fr) 2007-12-12
US7846442B2 (en) 2010-12-07
EP1593393B1 (fr) 2011-11-30
US20130064816A1 (en) 2013-03-14
HK1020011A1 (en) 2000-03-10
DK1941904T3 (da) 2012-07-16
DK1593393T3 (da) 2012-02-13
WO1998005357A1 (fr) 1998-02-12
AU3703597A (en) 1998-02-25
LU92004I2 (fr) 2012-07-23
DE69734317D1 (de) 2006-02-16
PT1593393E (pt) 2012-02-09
CA2791778A1 (fr) 1998-02-12
US20110014188A1 (en) 2011-01-20
ATE535255T1 (de) 2011-12-15
EP1941904B1 (fr) 2012-05-16
US20060099212A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
LU92098I2 (fr) Adalimumab et ses dérivés pharmaceutiquement acceptables (HUMIRA®)
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
GEP20002032B (en) (54) Pyrido[2,3-d]Pyrimidines and Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Composition Comprising Them and Methods of Treatment
MX9700081A (es) Composiciones farmaceuticas de tacrina.
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
GB8817015D0 (en) Method of treatment
NZ301645A (en) (R)-(-)-methyl phenyl oxazolidinone derivatives, pharmaceutical preparations and use for treating TNF stimulated diseases
GB9727131D0 (en) Therapeutic agents
DE69412662D1 (de) Angiotensin II-Antagonisten zur Behandlung von viralen Erkrankungen
SE8500996D0 (sv) Method of treatment
ATE237589T1 (de) Catecholdiether-derivate verwendbar als pharmazeutische mittel
WO2001037873A3 (fr) Methode et systeme permettant de supprimer l'inhibiteur de cytokines chez des patients
EP0338679A3 (fr) Utilisation du facteur necrosant des tumeurs dans le traitement du cancer de la vessie
MXPA02006146A (es) Uso de metabolitos bioactivos de gepirona para el tratamiento de desordenes psicologicos.
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
CA2392902A1 (fr) Bisindolylmaleimides substitues destines a inhiber la proliferation cellulaire
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
UA23882A (uk) Спосіб лікування виразкової хвороби дванадцятипало ї кишки
NZ505530A (en) Cytokine related treatments of disease using a nucleoside
RU94001168A (ru) Способ лечения больных пиелонефритом единственной почки